LITHANE 150 MG
LITHIUM CARBONATE : 150 MG · DIN 02013231 · SEARCHLIGHT PHARMA INC
Health Canada status: MARKETED
What is LITHANE?
LITHANE 150 MG contains LITHIUM CARBONATE : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02013231, held by SEARCHLIGHT PHARMA INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 23-Sep-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LITHANE used for?
Treatment of acute manic episodes in manic-depressive disorders; maintenance therapy to prevent or diminish relapses in bipolar manic-depressive patients.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02013231 |
|---|---|
| Brand name | LITHANE |
| Generic / active ingredient | LITHIUM CARBONATE : 150 MG |
| Manufacturer | SEARCHLIGHT PHARMA INC |
| Strength | 150 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N05AN01 LITHIUM |
| AHFS class | 28:28.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 23-Sep-2022 |
| Original market date | 1993-12-31 00:00:00 |
How is it administered?
Acute mania: 1800 mg/day initially (divided doses) to achieve 1-1.5 mmol/L serum levels. Maintenance: 600-1200 mg/day (divided doses) for serum levels 0.6-1.2 mmol/L.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly specified in provided text (refer to section 11 of full monograph).
How is it supplied?
150 mg: Bottles of 100 and 1000 capsules. 300 mg: Bottles of 1000 capsules.
Contraindications
Hypersensitivity; significant cardiovascular or renal disease; severe debilitation; severe dehydration; sodium depletion; brain damage; conditions requiring low sodium intake.
Warnings and precautions
Narrow therapeutic index; lithium toxicity can occur at therapeutic doses. Requires frequent serum monitoring (keep <1.5 mmol/L). Ensure adequate salt/fluid intake.
What can be used instead?
Other Canadian products sharing ATC code N05AN01 LITHIUM. 7 of 26 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-LITHIUM CARBONATE | 150 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02242837 |
| CARBOLITH | 150 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 00461733 |
| CARBOLITH | 600 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02011239 |
| LITHANE | 300 MG | CAPSULE | SEARCHLIGHT PHARMA INC | MARKETED | DIN 00406775 |
| LITHMAX | 300 MG | TABLET (EXTENDED-RELEASE) | AA PHARMA INC | MARKETED | DIN 02266695 |
| PMS-LITHIUM CARBONATE - CAP 150MG | 150 MG | CAPSULE | PHARMASCIENCE INC | MARKETED | DIN 02216132 |
| APO-LITHIUM CARBONATE | 300 MG | CAPSULE | APOTEX INC | DORMANT | DIN 02242838 |
| CARBOLITH | 300 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | DORMANT | DIN 00236683 |
| DOM-LITHIUM CARBONATE | 150 MG | CAPSULE | DOMINION PHARMACAL | CANCELLED PRE MARKET | DIN 02231397 |
| DOM-LITHIUM CARBONATE | 300 MG | CAPSULE | DOMINION PHARMACAL | CANCELLED PRE MARKET | DIN 02231398 |
Who else supplies LITHIUM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LITHIUM appears in 7 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.